Market research
2X1.F ABIVAX Société Anonyme
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.23
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0012333284
- Market cap
- 9B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.23
About
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 2X1.F discussion.
5 years, 5 months ago
ABIVAX Société Anonyme is currently in a long term uptrend where the price is trading 18.4% above its 200 day moving average.
From a valuation standpoint, the stock is 693.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 10427.3.
Finally, its free cash flow grew by 47.7% to $-4M since the same quarter in the previous year.
Based on the above factors, ABIVAX Société Anonyme gets an overall score of 2/5.